HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target

UroGen Pharma Ltd.

UroGen Pharma Ltd.

URGN

0.00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ: URGN) with a Buy and maintains $45 price target.